Spot Dx — Cheeky clue to peau d’orange and plaques
Jane is a 44-year-old who presents with a two-day history of a rash on the face. Test your clinical know-how by taking the quiz below.…
Tag: Immunotherapy
First subcutaneous immunotherapy for lung and liver cancers added to PBS
Thousands of Australians with advanced lung and liver cancer can now access subsidised subcutaneous immunotherapy that cuts treatment time to seven minutes. On 1 August,…
Aussie-wide immunotherapy program launched for infants with peanut allergy
Free oral immunotherapy will be offered to infants with peanut allergy nationwide under the first Australian treatment program of its kind outside of a clinical…
Immunological reset? CAR T-cell therapy shows promise for autoimmune diseases
Novel blood cancer immunotherapies could induce an “immunological reset” in patients with severe and treatment-refractory autoimmune disease, German rheumatologists report. In a case series of…
Perioperative immunotherapy a boon for patients with resectable NSCLC: study
Adults with resectable non-small cell lung cancer are five times more likely have complete pathological response with perioperative nivolumab plus neoadjuvant chemotherapy compared with chemotherapy…
First case report on Professor Scolyer’s experimental immunotherapy, 10 months in
Clinical details of Professor Richard Scolyer’s experimental glioblastoma therapy have been published for the first time, showing clear evidence that combination immunotherapy can cross the…
‘Fantastic news’: Dr Richard Scolyer posts his latest MRI brain scans on social media
Professor Richard Scolyer has reported more ‘fantastic’ news about his experimental brain tumour treatment for grade four glioblastoma. “Amazingly, my latest MRI brain scan shows…
Secondary primary malignancies ‘rare’ after CAR T-cell immunotherapy
The incidence of secondary primary malignancy after anti-CD19 chimeric antigen receptor T-cell immunotherapy is very low, according to a study in Nature Medicine. US researchers…
The AusDoc interview: Professor Richard Scolyer on his experimental glioblastoma treatment
Professors Richard Scolyer and Georgina Long were recently named Australians of the Year. It was for their work in the treatment of melanoma — they…
FDA investigates secondary malignancy risk with CAR T-cell therapy
The TGA is closely watching an overseas investigation of chimeric antigen receptor T-cell therapies after reports of secondary malignancies in treated patients. Last month, the…
